Global Bio Fund Sells Millions in Shares While Maintaining 19.9% Stake

Global biotech-focused investment firm RA Capital Management modestly trimmed its indirect stake in Vor Biopharma Inc. (VOR) by selling approximately 850,000 common shares on the U.S. market on April 2 and 6. The shares traded between $16.50 and $19.00 each, generating about $14.5 million (roughly KRW 20 billion) in proceeds and reducing RA Capital’s indirect holding to approximately 4.56 million shares.

In a Schedule 13D filing on April 8, RA Capital, its affiliated funds and individual investors reported a combined beneficial ownership of around 12.4 million shares—equal to a 19.9% stake when including derivatives—and clarified that the sale was simply profit-taking within a portfolio investment, with no new activist agenda planned.

Separately, Vor Biopharma has strengthened its financial runway through a private placement of about 5.3 million shares led by TCGX and others, raising roughly $75 million (about KRW 100 billion). Including prior financings over the past five months, the company has secured in excess of $330 million (mid-KRW 400 billion), extending its capital into early fiscal 2029.

Headquartered in Cambridge, Massachusetts, Vor Biopharma is a clinical-stage biotech developing treatments for autoimmune diseases—such as myasthenia gravis and Sjögren’s syndrome—centered on telitacicept, a bispecific fusion protein therapy in-licensed from China’s RemeGen. The company has begun dosing the first patient in its global Phase III telitacicept trial. With an expanding pipeline, Vor Biopharma is regarded as a long-term holding by major healthcare funds.